CLINICAL-SIGNIFICANCE OF SERUM FERRITIN IN PATIENTS WITH RENAL-CELL CARCINOMA

被引:28
作者
OZEN, H
UYGUR, C
SAHIN, A
TEKGUL, S
ERGEN, A
REMZI, D
机构
[1] Hacettepe Medical School, Department of Urology, Ankara
关键词
D O I
10.1016/S0090-4295(99)80261-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. We examined the serum ferritin levels in 158 patients with renal cell carcinoma and 101 healthy control subjects between 1987 and 1994 to investigate the value of this intracellular protein as a tumor marker. Methods. Preoperative and postoperative serum ferritin values were analyzed and the patients were stratified to three groups accordingly: group I, patients with normal values (N-N); group 2, those with preoperative high and postoperative normal (H-N); and group 3, those with preoperative normal or high with postoperative high ferritin levels (H-H). Results. The mean serum ferritin level in 101 healthy control subjects was 85.7 +/- 63.6 ng/mL (range, 3.7 to 265.2), The upper limit of normal, which was calculated by adding 2 standard deviations to the mean was 219,9 ng/mL. Mean serum ferritin in patients with renal cell carcinoma was 274.2 +/- 276.3 ng/mL, which was significantly higher than that of control values (P < 0.01). The sensitivity, specificity, and overall accuracy rate for ferritin increase was 94%, 50%, and 61%, respectively. Multivariate analysis showed that the aforementioned grouping and stage of the disease were the two independent prognostic parameters. Preoperative ferritin levels lost its significance on multivariate analysis. Conclusions. Our study shows that although serum ferritin was a useful toot in diagnosing and staging patients, it was not ideal in early stages. However serum ferritin seems to be more valuable for follow-up; postoperative values, indeed, predict the prognosis.
引用
收藏
页码:494 / 498
页数:5
相关论文
共 13 条
  • [1] TUMOR-SUPPRESSOR GENE ALLELIC LOSS IN HUMAN RENAL CANCERS
    BROOKS, JD
    BOVA, GS
    MARSHALL, FF
    ISAACS, WB
    [J]. JOURNAL OF UROLOGY, 1993, 150 (04) : 1278 - 1283
  • [2] COX DR, 1972, J R STAT SOC B, V34, P187
  • [3] CRAGG SJ, 1985, HUM GENET, V71, P108
  • [4] DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P229
  • [5] SERUM FERRITIN - A TUMOR-MARKER FOR RENAL-CELL CARCINOMA
    ESEN, A
    OZEN, H
    AYHAN, A
    ERGEN, A
    TASAR, C
    REMZI, F
    [J]. JOURNAL OF UROLOGY, 1991, 145 (06) : 1134 - 1137
  • [6] HANN HWL, 1980, CANCER RES, V40, P1411
  • [7] KOPRIVOVA H, 1986, NEOPLASMA, V33, P63
  • [8] PROGNOSTIC VALUE OF HISTOLOGICAL GRADE AND NUCLEAR GRADE IN RENAL ADENOCARCINOMA
    MARRONCLE, M
    IRANI, J
    DORE, B
    LEVILLAIN, P
    GOUJON, JM
    AUBERT, J
    [J]. JOURNAL OF UROLOGY, 1994, 151 (05) : 1174 - 1176
  • [9] MOROZ C, 1984, CANCER, V54, P84, DOI 10.1002/1097-0142(19840701)54:1<84::AID-CNCR2820540118>3.0.CO
  • [10] 2-T